A promising biomarker adaptive Phase 2/3 design – Explained and expanded
Authors:
Open Access
- 10 November 2023
- journal article
- editorial
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 36, 101229
Abstract
No abstract availableKeywords
Funding Information
- Michael Smith Health Research BC (SCH-2022-2553)
- Canada Research Chairs (CRC-2021-00232)
This publication has 7 references indexed in Scilit:
- To go or not to go in phase 2/3 oncology trials, a critical question with a unified answerContemporary Clinical Trials, 2023
- Extensions of the 2-in-1 adaptive designContemporary Clinical Trials, 2020
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2018
- Adaptive expansion of biomarker populations in phase 3 clinical trialsContemporary Clinical Trials, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentContemporary Clinical Trials, 2018
- Evaluation of Early Efficacy Endpoints for Proof-of-Concept TrialsJournal of Biopharmaceutical Statistics, 2013